UA93666C2 - Conjugates of insulin-like growth factor-1 (igf-1) and poly(ethylene glycol) - Google Patents

Conjugates of insulin-like growth factor-1 (igf-1) and poly(ethylene glycol)

Info

Publication number: UA93666C2
Authority: UA; Ukraine
Prior art keywords: igf; amino acid; poly; ethylene glycol; insulin
Prior art date: 2004-12-22

Application number

UAA200708134A

Other languages

English (en)

Inventor

Беат Амреин

Штефан Фозер

Курт Ланг

Фридрих Метцгер

Йорг Регула

Андреас Шаубмар

Фридерике Хессе

Клаус-Петер Кюнкеле

Мартин Ланцендьорфер

Original Assignee

Ф. Хоффманн-Ля Рош Аг

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-22

Filing date

2005-12-21

Publication date

2011-03-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34927913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA93666(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-12-21 Application filed by Ф. Хоффманн-Ля Рош Аг filed Critical Ф. Хоффманн-Ля Рош Аг

2011-03-10 Publication of UA93666C2 publication Critical patent/UA93666C2/ru

Links

-1 poly(ethylene glycol) Polymers 0.000 title abstract 6
229920001223 polyethylene glycol Polymers 0.000 title abstract 3
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 title abstract 2
102100037852 Insulin-like growth factor I Human genes 0.000 title abstract 2
101150088952 IGF1 gene Proteins 0.000 title 1
150000001413 amino acids Chemical class 0.000 abstract 6
KDXKERNSBIXSRK-UHFFFAOYSA-N lysine Chemical compound NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 4
239000004472 Lysine Substances 0.000 abstract 3
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
230000004075 alteration Effects 0.000 abstract 1
208000015122 neurodegenerative disease Diseases 0.000 abstract 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Epidemiology (AREA)
Toxicology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Immunology (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

UAA200708134A 2004-12-22 2005-12-21 Conjugates of insulin-like growth factor-1 (igf-1) and poly(ethylene glycol) UA93666C2 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP04030415A EP1674113A1 (en)	2004-12-22	2004-12-22	Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)

Publications (1)

Publication Number	Publication Date
UA93666C2 true UA93666C2 (en)	2011-03-10

Family

ID=34927913

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UAA200708134A UA93666C2 (en)	2004-12-22	2005-12-21	Conjugates of insulin-like growth factor-1 (igf-1) and poly(ethylene glycol)

Country Status (21)

Country	Link
US (5)	US20060154865A1 (ru)
EP (2)	EP1674113A1 (ru)
JP (1)	JP4954896B2 (ru)
KR (3)	KR101106860B1 (ru)
CN (1)	CN101123991B (ru)
AR (1)	AR052842A1 (ru)
AU (1)	AU2005318387B2 (ru)
BR (1)	BRPI0515857A (ru)
CA (1)	CA2592006C (ru)
CR (1)	CR9177A (ru)
EA (1)	EA011284B1 (ru)
IL (1)	IL183966A (ru)
MA (1)	MA29107B1 (ru)
MX (1)	MX2007007479A (ru)
NO (1)	NO20073103L (ru)
NZ (1)	NZ555840A (ru)
TN (1)	TNSN07237A1 (ru)
TW (3)	TW200940085A (ru)
UA (1)	UA93666C2 (ru)
WO (1)	WO2006066891A2 (ru)
ZA (1)	ZA200705146B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1674113A1 (en)	2004-12-22	2006-06-28	F. Hoffmann-La Roche Ag	Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
EP2032154A2 (en)	2006-06-09	2009-03-11	Novartis Ag	Stabilized insulin-like growth factor polypeptides
CN101484469B (zh)	2006-08-31	2012-12-12	弗·哈夫曼-拉罗切有限公司	生产胰岛素样生长因子-ⅰ的方法
CL2007002502A1 (es) *	2006-08-31	2008-05-30	Hoffmann La Roche	Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
RU2010144014A (ru) *	2008-04-03	2012-05-27	Ф. Хоффманн-Ля Рош Аг (Ch)	Применение пегилированных вариантов ифр-i для лечения нейромышечных расстройств
AU2009329911A1 (en) *	2008-12-23	2011-07-21	Salk Institute For Biological Studies	Method of treating neurodegenerative disease
CN102510757B (zh)	2009-07-22	2015-03-18	益普生制药股份有限公司	在第59位置处具有氨基酸替换的胰岛素样生长因子-1(igf-1)类似物
TW201138831A (en) *	2009-09-30	2011-11-16	Prolong Pharmaceuticals Inc	Modified granulocyte colony stimulating factor (G-CSF)
US20110152188A1 (en)	2009-12-23	2011-06-23	Hanns-Christian Mahler	Pharmaceutical compositions of igf/i proteins
EP2533813B1 (en) *	2010-02-11	2016-06-01	F.Hoffmann-La Roche Ag	Protein conjugates for trypsin mediated pegylation by transamidation and methods
CN101831067A (zh) *	2010-05-31	2010-09-15	王二新	聚乙二醇脂类缀合物及其在制备药物中的应用
US9637531B2 (en) *	2012-06-25	2017-05-02	The Brigham And Women's Hospital, Inc	Selective cartilage therapy
CU24308B1 (es)	2012-12-18	2018-01-10	Novartis Ag	Polipéptidos estabilizados del factor de crecimiento tipo insulina
CA2926173A1 (en)	2013-10-02	2015-04-09	Novartis Ag	Insulin-like growth factor mimetics for use in therapy
UY35874A (es)	2013-12-12	2015-07-31	Novartis Ag	Un proceso para la preparación de una composición de proteínas pegiladas
CA2997947A1 (en) *	2015-09-09	2017-03-16	The Trustees Of Columbia University In The City Of New York	Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
KR200481741Y1 (ko)	2016-02-22	2016-11-04	강진범	차량의 방향지시등에 연동하여 특수 인식 영역에 led 반사광을 형성하기 위한 노면 광조사 장치
WO2017147298A1 (en)	2016-02-23	2017-08-31	The Regents Of The University Of Colorado, A Body Corporate	Peptide-based methods for treating neurological injury
RU2711111C1 (ru) *	2018-09-05	2020-01-15	Илья Владимирович Духовлинов	Гибридный белок igf-1-long для лечения инсульта, нуклеиновая кислота, вектор, клетка, фармацевтическая композиция, способ лечения
EP3911668A1 (en)	2019-01-18	2021-11-24	The Regents of the University of Colorado, a body corporate	Amphipathic alpha-helical antimicrobial peptides treat infections by gram-negative pathogens
US12222354B2 (en)	2021-03-19	2025-02-11	Quest Diagnostics Investments Llc	Identification and quantitation of insulin-like growth factor-I variants by mass spectrometry
WO2024138064A1 (en) *	2022-12-22	2024-06-27	Cavalry Biosciences, Inc.	Compositions and methods for treating meibomain gland dysfunction

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3486216T2 (de)	1983-04-25	1994-02-17	Chiron Corp	Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren.
IL71991A (en)	1983-06-06	1994-05-30	Genentech Inc	Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US4904584A (en)	1987-12-23	1990-02-27	Genetics Institute, Inc.	Site-specific homogeneous modification of polypeptides
DE3852636T2 (de) *	1987-12-24	1995-05-04	Gropep Pty Ltd	Peptid-analoge vom insulinähnlichen wachstums-faktor 1 (igf-1) oder faktor 2 (igf-2).
ES2085297T3 (es)	1989-05-27	1996-06-01	Sumitomo Pharma	Procedimiento para preparar derivados de poli(etilenglicol) y proteina modificada.
DE3924705A1 (de)	1989-07-26	1991-01-31	Boehringer Mannheim Gmbh	Heterobifunktionelle verbindungen
US5681814A (en)	1990-06-07	1997-10-28	Genentech, Inc.	Formulated IGF-I Composition
JP3051145B2 (ja) *	1990-08-28	2000-06-12	住友製薬株式会社	新規なポリエチレングリコール誘導体修飾ペプチド
US5861373A (en) *	1991-08-01	1999-01-19	Genentech, Inc	IGF-1 to improve the neural condition
WO1993002695A1 (en)	1991-08-01	1993-02-18	Genentech, Inc.	Igf-1 to improve the neural condition
EP0679095A1 (en) *	1992-11-25	1995-11-02	Amgen Boulder Inc.	Modified insulin-like growth factors
AU2601895A (en) *	1994-05-24	1995-12-18	Amgen Boulder Inc.	Modified insulin-like growth factors
US5824784A (en)	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
US5932462A (en) *	1995-01-10	1999-08-03	Shearwater Polymers, Inc.	Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5672662A (en) *	1995-07-07	1997-09-30	Shearwater Polymers, Inc.	Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
EP1017794A1 (en) *	1997-02-06	2000-07-12	Novo Nordisk A/S	Polypeptide-polymer conjugates having added and/or removed attachment groups
US6767892B1 (en)	1997-11-07	2004-07-27	Chrion Corporation	Compositions providing for increased IGF-I solubility
US7067485B2 (en)	1997-11-07	2006-06-27	Chiron Corporation	IGF-I composition and its use
WO1999055362A1 (en)	1998-04-29	1999-11-04	Genentech, Inc.	Spray dried formulations of igf-i
US6436897B2 (en)	1998-06-01	2002-08-20	Celtrix Pharmaceuticals, Inc.	Pharmaceutical formulations for IGF/IGFBP
US6451986B1 (en)	1998-06-22	2002-09-17	Immunex Corporation	Site specific protein modification
JP3971108B2 (ja) *	1999-01-06	2007-09-05	ジェネンテック・インコーポレーテッド	インシュリン様成長因子（ｉｇｆ）ｉ突然変異体
CA2356257C (en) *	1999-01-06	2012-10-16	Genentech, Inc.	Insulin-like growth factor (igf) i mutant variants
AU763039B2 (en)	1999-04-08	2003-07-10	Genentech Inc.	Composition based on oppositely-charged polypeptides
JP2003527090A (ja) *	1999-08-27	2003-09-16	マキシゲン・エイピーエス	新規なインターフェロンベータ様分子
US7431921B2 (en)	1999-08-27	2008-10-07	Maxygen Aps	Interferon beta-like molecules
EP1286700A2 (en) *	2000-06-01	2003-03-05	Universite Catholique De Louvain	Tumor activated prodrug compounds
US20040014652A1 (en) *	2000-06-01	2004-01-22	Andre Trouet	Tumor activated prodrug compounds and methods of making and using the same
WO2002032449A2 (en)	2000-10-13	2002-04-25	Chiron Corporation	Method for treating ischemic events affecting the central nervous system
NZ541122A (en) *	2002-12-26	2008-09-26	Mountain View Pharmaceuticals	Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity
EP1674113A1 (en)	2004-12-22	2006-06-28	F. Hoffmann-La Roche Ag	Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol)
CL2007002502A1 (es)	2006-08-31	2008-05-30	Hoffmann La Roche	Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
RU2010144014A (ru)	2008-04-03	2012-05-27	Ф. Хоффманн-Ля Рош Аг (Ch)	Применение пегилированных вариантов ифр-i для лечения нейромышечных расстройств

2004
- 2004-12-22 EP EP04030415A patent/EP1674113A1/en not_active Withdrawn
2005
- 2005-12-20 US US11/313,101 patent/US20060154865A1/en not_active Abandoned
- 2005-12-21 CN CN2005800485069A patent/CN101123991B/zh not_active Expired - Fee Related
- 2005-12-21 NZ NZ555840A patent/NZ555840A/en not_active IP Right Cessation
- 2005-12-21 BR BRPI0515857-5A patent/BRPI0515857A/pt not_active Application Discontinuation
- 2005-12-21 KR KR1020097014300A patent/KR101106860B1/ko not_active Expired - Fee Related
- 2005-12-21 CA CA2592006A patent/CA2592006C/en not_active Expired - Fee Related
- 2005-12-21 UA UAA200708134A patent/UA93666C2/ru unknown
- 2005-12-21 TW TW098120879A patent/TW200940085A/zh unknown
- 2005-12-21 MX MX2007007479A patent/MX2007007479A/es active IP Right Grant
- 2005-12-21 WO PCT/EP2005/013756 patent/WO2006066891A2/en active Application Filing
- 2005-12-21 TW TW097145363A patent/TW200914041A/zh unknown
- 2005-12-21 JP JP2007547330A patent/JP4954896B2/ja not_active Expired - Fee Related
- 2005-12-21 KR KR1020077016867A patent/KR100915278B1/ko not_active Expired - Fee Related
- 2005-12-21 AU AU2005318387A patent/AU2005318387B2/en not_active Ceased
- 2005-12-21 TW TW094145672A patent/TW200635604A/zh unknown
- 2005-12-21 EA EA200701234A patent/EA011284B1/ru not_active IP Right Cessation
- 2005-12-21 KR KR1020097000308A patent/KR20090010138A/ko not_active Withdrawn
- 2005-12-21 EP EP05849990.6A patent/EP1830889B1/en active Active
- 2005-12-22 AR ARP050105473A patent/AR052842A1/es not_active Application Discontinuation
2007
- 2007-06-12 CR CR9177A patent/CR9177A/es not_active Application Discontinuation
- 2007-06-14 IL IL183966A patent/IL183966A/en not_active IP Right Cessation
- 2007-06-18 NO NO20073103A patent/NO20073103L/no not_active Application Discontinuation
- 2007-06-21 MA MA30023A patent/MA29107B1/fr unknown
- 2007-06-21 ZA ZA200705146A patent/ZA200705146B/en unknown
- 2007-06-21 TN TNP2007000237A patent/TNSN07237A1/fr unknown
2010
- 2010-06-02 US US12/791,904 patent/US20110009317A1/en not_active Abandoned
2012
- 2012-07-18 US US13/551,648 patent/US20120322732A1/en not_active Abandoned
2013
- 2013-03-18 US US13/845,179 patent/US20130217623A1/en not_active Abandoned
2014
- 2014-09-10 US US14/482,703 patent/US9724425B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
KR20070088809A (ko)	2007-08-29
TW200914041A (en)	2009-04-01
EP1830889B1 (en)	2017-05-17
KR20090089457A (ko)	2009-08-21
US20120322732A1 (en)	2012-12-20
CN101123991A (zh)	2008-02-13
IL183966A (en)	2012-01-31
JP4954896B2 (ja)	2012-06-20
US20130217623A1 (en)	2013-08-22
ZA200705146B (en)	2008-06-25
EP1830889A2 (en)	2007-09-12
AU2005318387A1 (en)	2006-06-29
TW200940085A (en)	2009-10-01
CR9177A (es)	2007-11-23
KR101106860B1 (ko)	2012-01-19
CA2592006A1 (en)	2006-06-29
MA29107B1 (fr)	2007-12-03
CN101123991B (zh)	2011-03-16
EA011284B1 (ru)	2009-02-27
KR100915278B1 (ko)	2009-09-03
JP2008524296A (ja)	2008-07-10
US20150099699A1 (en)	2015-04-09
AU2005318387B2 (en)	2011-07-21
NZ555840A (en)	2010-02-26
US20060154865A1 (en)	2006-07-13
TW200635604A (en)	2006-10-16
US9724425B2 (en)	2017-08-08
NO20073103L (no)	2007-09-19
EA200701234A1 (ru)	2007-12-28
KR20090010138A (ko)	2009-01-28
US20110009317A1 (en)	2011-01-13
WO2006066891A2 (en)	2006-06-29
WO2006066891A3 (en)	2007-05-31
IL183966A0 (en)	2007-10-31
BRPI0515857A (pt)	2008-08-12
TNSN07237A1 (fr)	2008-11-21
AR052842A1 (es)	2007-04-04
MX2007007479A (es)	2007-07-20
CA2592006C (en)	2015-01-27
EP1674113A1 (en)	2006-06-28

Publication	Publication Date	Title
UA93666C2 (en)	2011-03-10	Conjugates of insulin-like growth factor-1 (igf-1) and poly(ethylene glycol)
WO2007056362A3 (en)	2009-04-23	Glucagon analogs exhibiting physiological solubility and stability
RU2010144014A (ru)	2012-05-27	Применение пегилированных вариантов ифр-i для лечения нейромышечных расстройств
JP2018015005A5 (ru)	2018-07-19
JP2013543497A5 (ru)	2014-11-13
IL213319A (en)	2017-07-31	Polylysis peptides for use in the treatment of bacterial infections
RU2010137915A (ru)	2012-03-20	Полипептиды апортинина для транспорта соединения через гематоэнцефалический барьер
HK1140420A1 (en)	2010-10-15	Reconstituted surfactants having improved properties
RU2012106116A (ru)	2013-08-27	Вариантные формы уратоксидазы и их применение
WO2007043048A3 (en)	2007-11-01	Self-assembled fmoc-ff hydrogels
WO2007067979A3 (en)	2008-07-31	Targeting vector-phospholipid conjugates
WO2001051510A3 (en)	2002-03-21	G-csf conjugates
WO2009067639A3 (en)	2009-07-09	Variants of c-type natriuretic peptide
WO2007062610A3 (es)	2007-09-20	Dendrímero con peg de cuatro ramas para la conjugación a proteínas y péptidos
CA2345027A1 (en)	2000-04-20	Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
PL1638594T3 (pl)	2011-08-31	Kompozycja polipeptydu HIP/PAP do zastosowania do regeneracji wątroby i do zapobiegania niewydolności wątroby
JP2006506942A5 (ru)	2006-04-13
WO2004027064A3 (en)	2004-11-18	Ghrh analogues
WO2001009163A3 (en)	2001-09-07	Improvement of peptide transport by conjugation with bile acids
WO2005099769A3 (en)	2006-05-26	Novel g-csf conjugates
WO2009035092A1 (ja)	2009-03-19	新規なポリペプチドおよびその製造方法
WO2010028066A3 (en)	2010-09-02	Cd133 epitopes
WO2006056885A3 (en)	2006-09-14	Igf-1 isoforms
RU2012130606A (ru)	2014-01-27	Фармацевтические композиции, содержащие белки igf-i, буферное вещество и вещество, регулирующее тоничность
WO2008047370A3 (en)	2008-06-19	Compositions and methods for inducing angiogenesis